BioCentury | Jun 26, 2019
Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

...has the anti-RTN4 mAb ATI355 in Phase I testing for spinal cord injury (SCI). TARGET/MARKER/PATHWAY: Reticulon...
...Switzerland email: CONTACT: Martin E. Schwab, same affiliation as above email: Claire Quang University of Zurich Reticulon...
BioCentury | May 15, 2018
Distillery Therapeutics


...testing to treat depression and neurobehavioral disorders. TARGET/MARKER/PATHWAY: Opioid related nociceptin receptor 1 (OPRL1; NOPR); reticulon...
...School of Medicine, New Haven, Conn. email: Hongjiang Li Yale University Opioid related nociceptin receptor 1 (OPRL1) (NOPR) Reticulon...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

...School of Public Health Preclinical News Infectious disease Dengue fever; West Nile virus; Zika virus Reticulon...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Infectious disease

...identifying and testing RTN3 inhibitors in models of dengue fever, West Nile and Zika. TARGET/MARKER/PATHWAY: Reticulon... the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia email: Hongjiang Li University of Melbourne Reticulon...
BioCentury | Jan 11, 2017
Distillery Therapeutics


...reticulon 4 receptor-like 2 (RTN4RL2; NgR2); myelin associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon...
...associated glycoprotein (MAG) Oligodendrocyte myelin glycoprotein (OMG) (OMGP) Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B) Reticulon 4 receptor (RTN4R) (NGR) Reticulon...
BioCentury | Jan 7, 2016


...dextran amine. In a mouse model of SCI with CRYM-driven GFP expression, fluorescent imaging showed reticulon...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; stroke Reticulon 4 (RTN4...
BioCentury | Jul 29, 2013
Company News

GlaxoSmithKline neurology news

...ways that could be seen as bribery. Ozanezumab ( 1223249 ), a humanized mAb against reticulon...
BioCentury | Jan 21, 2013
Product Development

Solving the ALS maze

...skeletal muscle troponin activator Ph II GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Ozanezumab (1223249) Humanized mAb against reticulon...
BioCentury | Dec 10, 2012
Company News

AlphaCore Pharma LLC, Axerion Therapeutics, Optimum Therapeutics LLC, NIH cancer, cardiovascular, neurology news

...third project is a reticulon 4 receptor ( RTN4R ; NGR ) decoy that binds reticulon...
Items per page:
1 - 10 of 30